Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Proto

Showing results (551-560 of 595) with videos related to

Pageof 60
Sort By:
Cancer Research Communications|March 25, 2026
Mapping genomic heterogeneity in paediatric and adolescent-young adult sarcomas: insights from the Italian SAR-GEN2016 and SAR-GEN_ITA prospective multicenter trialsElisa Tirtei, Valeria Difilippo, Federico Divincenzo, et al.
Lung Cancer (Amsterdam, Netherlands)|November 1, 2020
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY studyMelissa Bersanelli, Sebastiano Buti, Diana Giannarelli, et al.
Autoimmunity Reviews|May 8, 2020
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, ItalyPaola Toniati, Simone Piva, Marco Cattalini, et al.
Clinical Lung Cancer|January 23, 2024
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational ResearchArsela Prelaj, Monica Ganzinelli, Leonardo Provenzano, et al.
Clinical Lung Cancer|July 19, 2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical OutcomesAlessio Cortellini, Alex Friedlaender, Giuseppe L Banna, et al.
NPJ Precision Oncology|January 29, 2026
APOLLO11: a bio-data-driven model for clinical and translational research in lung cancerArsela Prelaj, Leonardo Provenzano, Vanja Miskovic, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.
Nature|June 19, 2015
A novel multiple-stage antimalarial agent that inhibits protein synthesisBeatriz Baragaña, Irene Hallyburton, Marcus C S Lee, et al.
Nature Microbiology|August 18, 2022
Genomic epidemiology of the SARS-CoV-2 epidemic in BrazilMarta Giovanetti, Svetoslav Nanev Slavov, Vagner Fonseca, et al.
Medrxiv : the Preprint Server for Health Sciences|April 5, 2022
Genomic epidemiology reveals the impact of national and international restrictions measures on the SARS-CoV-2 epidemic in BrazilMarta Giovanetti, Svetoslav Nanev Slavov, Vagner Fonseca, et al.
Pageof 60

Showing results (551-560 of 595) with videos related to

Sort By:
Pageof 60
Cancer Research Communications|March 25, 2026
Mapping genomic heterogeneity in paediatric and adolescent-young adult sarcomas: insights from the Italian SAR-GEN2016 and SAR-GEN_ITA prospective multicenter trialsElisa Tirtei, Valeria Difilippo, Federico Divincenzo, et al.
Lung Cancer (Amsterdam, Netherlands)|November 1, 2020
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY studyMelissa Bersanelli, Sebastiano Buti, Diana Giannarelli, et al.
Autoimmunity Reviews|May 8, 2020
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, ItalyPaola Toniati, Simone Piva, Marco Cattalini, et al.
Clinical Lung Cancer|January 23, 2024
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational ResearchArsela Prelaj, Monica Ganzinelli, Leonardo Provenzano, et al.
Clinical Lung Cancer|July 19, 2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical OutcomesAlessio Cortellini, Alex Friedlaender, Giuseppe L Banna, et al.
NPJ Precision Oncology|January 29, 2026
APOLLO11: a bio-data-driven model for clinical and translational research in lung cancerArsela Prelaj, Leonardo Provenzano, Vanja Miskovic, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.
Nature|June 19, 2015
A novel multiple-stage antimalarial agent that inhibits protein synthesisBeatriz Baragaña, Irene Hallyburton, Marcus C S Lee, et al.
Nature Microbiology|August 18, 2022
Genomic epidemiology of the SARS-CoV-2 epidemic in BrazilMarta Giovanetti, Svetoslav Nanev Slavov, Vagner Fonseca, et al.
Medrxiv : the Preprint Server for Health Sciences|April 5, 2022
Genomic epidemiology reveals the impact of national and international restrictions measures on the SARS-CoV-2 epidemic in BrazilMarta Giovanetti, Svetoslav Nanev Slavov, Vagner Fonseca, et al.
Pageof 60